Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04985721
Title A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD)
Acronym IMPARP-HRD
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Peter MacCallum Cancer Centre, Australia
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS

Additional content available in CKB BOOST